FDA GFI, Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA, DRAFT, 08/21 Beatrice Burtsov2022-01-28T10:12:09+00:00January 28th, 2022| About the Author: Beatrice Burtsov